The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
GCLLSG 2016 | Potential concerns with ventoclax and Richter’s transformation
Barbara Eichhorst, MD of the University of Cologne, Cologne, Germany, discusses potential concerns with venetoclax. The advantage of venetoclax is that the drug is administered for a certain time period (up to 12 months). What is seen so far in frontline therapy, is that all patients respond to this therapy. There is concern, however, regarding the incidence rate of Richter’s transformation, as it still holds a very poor prognosis. Furthermore, with late toxicities, more Richter’s transformation could occur. However, these observations are based heavily on pre-treated patients with 17p deletion where it is known that they have a significant risk of developing Richter’s syndrome. Dr. Eichhorst notes that these patients are to be monitored extremely carefully in frontline therapy. Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.
